Categories Earnings, Health Care

Earnings Summary: Charles River Laboratories reports Q2 2023 results

Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023.

  • For the quarter, the company reported revenues of $1.06 billion, up 8.9% from $973.1 million recorded in the prior-year quarter
  • Net income attributable to common shareholders was $97.0 million in Q2, compared to $109.3 million for the same period in 2022
  • On a per-share basis, Q2 unadjusted earnings decreased 11.3% year-over-year to $1.89 from $2.13 last year
  • Adjusted profit was $138.3 million in the June quarter, which is down 2.5% from the prior-year period
  • Earnings per share, on an adjusted basis, decreased 2.9% year-over-year to $2.69 during the three-month period
  • The management expects revenues to increase in the range of 2.5% to 4.5% in fiscal 2023

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

LandBridge Company gears up to raise $319 million in US IPO

LandBridge Company LLC, which is engaged in the acquisition of oil properties, is preparing to become a public entity by listing on the New York Stock Exchange through an initial

A look at the performance of Philip Morris’ (PM) smoke-free business

Shares of Philip Morris International Inc. (NYSE: PM) stayed red on Monday. The stock has gained 7% over the past three months. The company has been seeing its smoke-free business

Kroger (KR) to report Q1 earnings on Thursday. Here’s what to expect

Grocery chain The Kroger Co. (NYSE: KR) is preparing to report financial results for the first three months of fiscal 2024, with market watchers forecasting a modest outcome. Betting on

Add Comment
Viewing Highlight